

Global Systemic Sclerosis Drug Market Growth 2024-2030

<https://marketpublishers.com/r/GE1A189D9E9FEN.html>

Date: February 2024

Pages: 137

Price: US\$ 3,660.00 (Single User License)

ID: GE1A189D9E9FEN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

According to our LPI (LP Information) latest study, the global Systemic Sclerosis Drug market size was valued at US\$ million in 2023. With growing demand in downstream market, the Systemic Sclerosis Drug is forecast to a readjusted size of US\$ million by 2030 with a CAGR of % during review period.

The research report highlights the growth potential of the global Systemic Sclerosis Drug market. Systemic Sclerosis Drug are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Systemic Sclerosis Drug. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Systemic Sclerosis Drug market.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market

and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Key Features:

The report on Systemic Sclerosis Drug market reflects various aspects and provide valuable insights into the industry.

Market Size and Growth: The research report provide an overview of the current size and growth of the Systemic Sclerosis Drug market. It may include historical data, market segmentation by Type (e.g., ARG-201, Belimumab), and regional breakdowns.

Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Systemic Sclerosis Drug market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.

Competitive Landscape: The research report provides analysis of the competitive landscape within the Systemic Sclerosis Drug market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.

Technological Developments: The research report can delve into the latest technological developments in the Systemic Sclerosis Drug industry. This include advancements in Systemic Sclerosis Drug technology, Systemic Sclerosis Drug new entrants, Systemic Sclerosis Drug new investment, and other innovations that are shaping the future of Systemic Sclerosis Drug.

Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Systemic Sclerosis Drug market. It includes factors influencing customer ' purchasing decisions, preferences for Systemic Sclerosis Drug product.

Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Systemic Sclerosis Drug market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other

measures aimed at promoting Systemic Sclerosis Drug market. The report also evaluates the effectiveness of these policies in driving market growth.

Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Systemic Sclerosis Drug market.

Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Systemic Sclerosis Drug industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.

Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Systemic Sclerosis Drug market.

Market Segmentation:

Systemic Sclerosis Drug market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.

Segmentation by type

ARG-201

Belimumab

BL-1110

BOT-191

C-82

Others

Segmentation by application

Hospital

Clinic

ASCs

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Allergan Plc

Angion Biomedica Corp.

arGentis Pharmaceuticals, LLC

Bayer AG

BioLineRx, Ltd.

BiOrion Technologies B.V.

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Corbus pharmaceuticals, Inc.

CSL Limited

Daval International Limited

Digna Biotech, S.L.

F. Hoffmann-La Roche Ltd.

Fibrocell Science, Inc.

GenKyoTex S.A.

GlaxoSmithKline Plc

Key Questions Addressed in this Report

What is the 10-year outlook for the global Systemic Sclerosis Drug market?

What factors are driving Systemic Sclerosis Drug market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Systemic Sclerosis Drug market opportunities vary by end market size?

How does Systemic Sclerosis Drug break out type, application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Systemic Sclerosis Drug Annual Sales 2019-2030
 - 2.1.2 World Current & Future Analysis for Systemic Sclerosis Drug by Geographic Region, 2019, 2023 & 2030
 - 2.1.3 World Current & Future Analysis for Systemic Sclerosis Drug by Country/Region, 2019, 2023 & 2030
- 2.2 Systemic Sclerosis Drug Segment by Type
 - 2.2.1 ARG-201
 - 2.2.2 Belimumab
 - 2.2.3 BL-1110
 - 2.2.4 BOT-191
 - 2.2.5 C-82
 - 2.2.6 Others
- 2.3 Systemic Sclerosis Drug Sales by Type
 - 2.3.1 Global Systemic Sclerosis Drug Sales Market Share by Type (2019-2024)
 - 2.3.2 Global Systemic Sclerosis Drug Revenue and Market Share by Type (2019-2024)
 - 2.3.3 Global Systemic Sclerosis Drug Sale Price by Type (2019-2024)
- 2.4 Systemic Sclerosis Drug Segment by Application
 - 2.4.1 Hospital
 - 2.4.2 Clinic
 - 2.4.3 ASCs
 - 2.4.4 Others
- 2.5 Systemic Sclerosis Drug Sales by Application

- 2.5.1 Global Systemic Sclerosis Drug Sale Market Share by Application (2019-2024)
- 2.5.2 Global Systemic Sclerosis Drug Revenue and Market Share by Application (2019-2024)
- 2.5.3 Global Systemic Sclerosis Drug Sale Price by Application (2019-2024)

3 GLOBAL SYSTEMIC SCLEROSIS DRUG BY COMPANY

- 3.1 Global Systemic Sclerosis Drug Breakdown Data by Company
 - 3.1.1 Global Systemic Sclerosis Drug Annual Sales by Company (2019-2024)
 - 3.1.2 Global Systemic Sclerosis Drug Sales Market Share by Company (2019-2024)
- 3.2 Global Systemic Sclerosis Drug Annual Revenue by Company (2019-2024)
 - 3.2.1 Global Systemic Sclerosis Drug Revenue by Company (2019-2024)
 - 3.2.2 Global Systemic Sclerosis Drug Revenue Market Share by Company (2019-2024)
- 3.3 Global Systemic Sclerosis Drug Sale Price by Company
- 3.4 Key Manufacturers Systemic Sclerosis Drug Producing Area Distribution, Sales Area, Product Type
 - 3.4.1 Key Manufacturers Systemic Sclerosis Drug Product Location Distribution
 - 3.4.2 Players Systemic Sclerosis Drug Products Offered
- 3.5 Market Concentration Rate Analysis
 - 3.5.1 Competition Landscape Analysis
 - 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
- 3.6 New Products and Potential Entrants
- 3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR SYSTEMIC SCLEROSIS DRUG BY GEOGRAPHIC REGION

- 4.1 World Historic Systemic Sclerosis Drug Market Size by Geographic Region (2019-2024)
 - 4.1.1 Global Systemic Sclerosis Drug Annual Sales by Geographic Region (2019-2024)
 - 4.1.2 Global Systemic Sclerosis Drug Annual Revenue by Geographic Region (2019-2024)
- 4.2 World Historic Systemic Sclerosis Drug Market Size by Country/Region (2019-2024)
 - 4.2.1 Global Systemic Sclerosis Drug Annual Sales by Country/Region (2019-2024)
 - 4.2.2 Global Systemic Sclerosis Drug Annual Revenue by Country/Region (2019-2024)
- 4.3 Americas Systemic Sclerosis Drug Sales Growth

4.4 APAC Systemic Sclerosis Drug Sales Growth

4.5 Europe Systemic Sclerosis Drug Sales Growth

4.6 Middle East & Africa Systemic Sclerosis Drug Sales Growth

5 AMERICAS

5.1 Americas Systemic Sclerosis Drug Sales by Country

5.1.1 Americas Systemic Sclerosis Drug Sales by Country (2019-2024)

5.1.2 Americas Systemic Sclerosis Drug Revenue by Country (2019-2024)

5.2 Americas Systemic Sclerosis Drug Sales by Type

5.3 Americas Systemic Sclerosis Drug Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Systemic Sclerosis Drug Sales by Region

6.1.1 APAC Systemic Sclerosis Drug Sales by Region (2019-2024)

6.1.2 APAC Systemic Sclerosis Drug Revenue by Region (2019-2024)

6.2 APAC Systemic Sclerosis Drug Sales by Type

6.3 APAC Systemic Sclerosis Drug Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Systemic Sclerosis Drug by Country

7.1.1 Europe Systemic Sclerosis Drug Sales by Country (2019-2024)

7.1.2 Europe Systemic Sclerosis Drug Revenue by Country (2019-2024)

7.2 Europe Systemic Sclerosis Drug Sales by Type

7.3 Europe Systemic Sclerosis Drug Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Systemic Sclerosis Drug by Country

8.1.1 Middle East & Africa Systemic Sclerosis Drug Sales by Country (2019-2024)

8.1.2 Middle East & Africa Systemic Sclerosis Drug Revenue by Country (2019-2024)

8.2 Middle East & Africa Systemic Sclerosis Drug Sales by Type

8.3 Middle East & Africa Systemic Sclerosis Drug Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Systemic Sclerosis Drug

10.3 Manufacturing Process Analysis of Systemic Sclerosis Drug

10.4 Industry Chain Structure of Systemic Sclerosis Drug

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Systemic Sclerosis Drug Distributors

11.3 Systemic Sclerosis Drug Customer

12 WORLD FORECAST REVIEW FOR SYSTEMIC SCLEROSIS DRUG BY GEOGRAPHIC REGION

12.1 Global Systemic Sclerosis Drug Market Size Forecast by Region

12.1.1 Global Systemic Sclerosis Drug Forecast by Region (2025-2030)

12.1.2 Global Systemic Sclerosis Drug Annual Revenue Forecast by Region (2025-2030)

12.2 Americas Forecast by Country

12.3 APAC Forecast by Region

12.4 Europe Forecast by Country

12.5 Middle East & Africa Forecast by Country

12.6 Global Systemic Sclerosis Drug Forecast by Type

12.7 Global Systemic Sclerosis Drug Forecast by Application

13 KEY PLAYERS ANALYSIS

13.1 Allergan Plc

13.1.1 Allergan Plc Company Information

13.1.2 Allergan Plc Systemic Sclerosis Drug Product Portfolios and Specifications

13.1.3 Allergan Plc Systemic Sclerosis Drug Sales, Revenue, Price and Gross Margin (2019-2024)

13.1.4 Allergan Plc Main Business Overview

13.1.5 Allergan Plc Latest Developments

13.2 Angion Biomedica Corp.

13.2.1 Angion Biomedica Corp. Company Information

13.2.2 Angion Biomedica Corp. Systemic Sclerosis Drug Product Portfolios and Specifications

13.2.3 Angion Biomedica Corp. Systemic Sclerosis Drug Sales, Revenue, Price and Gross Margin (2019-2024)

13.2.4 Angion Biomedica Corp. Main Business Overview

13.2.5 Angion Biomedica Corp. Latest Developments

13.3 arGentis Pharmaceuticals, LLC

13.3.1 arGentis Pharmaceuticals, LLC Company Information

13.3.2 arGentis Pharmaceuticals, LLC Systemic Sclerosis Drug Product Portfolios and Specifications

13.3.3 arGentis Pharmaceuticals, LLC Systemic Sclerosis Drug Sales, Revenue, Price and Gross Margin (2019-2024)

13.3.4 arGentis Pharmaceuticals, LLC Main Business Overview

13.3.5 arGentis Pharmaceuticals, LLC Latest Developments

13.4 Bayer AG

13.4.1 Bayer AG Company Information

13.4.2 Bayer AG Systemic Sclerosis Drug Product Portfolios and Specifications

13.4.3 Bayer AG Systemic Sclerosis Drug Sales, Revenue, Price and Gross Margin (2019-2024)

13.4.4 Bayer AG Main Business Overview

13.4.5 Bayer AG Latest Developments

13.5 BioLineRx, Ltd.

13.5.1 BioLineRx, Ltd. Company Information

13.5.2 BioLineRx, Ltd. Systemic Sclerosis Drug Product Portfolios and Specifications

13.5.3 BioLineRx, Ltd. Systemic Sclerosis Drug Sales, Revenue, Price and Gross Margin (2019-2024)

13.5.4 BioLineRx, Ltd. Main Business Overview

13.5.5 BioLineRx, Ltd. Latest Developments

13.6 BiOrion Technologies B.V.

13.6.1 BiOrion Technologies B.V. Company Information

13.6.2 BiOrion Technologies B.V. Systemic Sclerosis Drug Product Portfolios and Specifications

13.6.3 BiOrion Technologies B.V. Systemic Sclerosis Drug Sales, Revenue, Price and Gross Margin (2019-2024)

13.6.4 BiOrion Technologies B.V. Main Business Overview

13.6.5 BiOrion Technologies B.V. Latest Developments

13.7 Boehringer Ingelheim GmbH

13.7.1 Boehringer Ingelheim GmbH Company Information

13.7.2 Boehringer Ingelheim GmbH Systemic Sclerosis Drug Product Portfolios and Specifications

13.7.3 Boehringer Ingelheim GmbH Systemic Sclerosis Drug Sales, Revenue, Price and Gross Margin (2019-2024)

13.7.4 Boehringer Ingelheim GmbH Main Business Overview

13.7.5 Boehringer Ingelheim GmbH Latest Developments

13.8 Bristol-Myers Squibb Company

13.8.1 Bristol-Myers Squibb Company Company Information

13.8.2 Bristol-Myers Squibb Company Systemic Sclerosis Drug Product Portfolios and Specifications

13.8.3 Bristol-Myers Squibb Company Systemic Sclerosis Drug Sales, Revenue, Price and Gross Margin (2019-2024)

13.8.4 Bristol-Myers Squibb Company Main Business Overview

13.8.5 Bristol-Myers Squibb Company Latest Developments

13.9 Corbus pharmaceuticals, Inc.

- 13.9.1 Corbus pharmaceuticals, Inc. Company Information
- 13.9.2 Corbus pharmaceuticals, Inc. Systemic Sclerosis Drug Product Portfolios and Specifications
- 13.9.3 Corbus pharmaceuticals, Inc. Systemic Sclerosis Drug Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.9.4 Corbus pharmaceuticals, Inc. Main Business Overview
- 13.9.5 Corbus pharmaceuticals, Inc. Latest Developments
- 13.10 CSL Limited
 - 13.10.1 CSL Limited Company Information
 - 13.10.2 CSL Limited Systemic Sclerosis Drug Product Portfolios and Specifications
 - 13.10.3 CSL Limited Systemic Sclerosis Drug Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.10.4 CSL Limited Main Business Overview
 - 13.10.5 CSL Limited Latest Developments
- 13.11 Daval International Limited
 - 13.11.1 Daval International Limited Company Information
 - 13.11.2 Daval International Limited Systemic Sclerosis Drug Product Portfolios and Specifications
 - 13.11.3 Daval International Limited Systemic Sclerosis Drug Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.11.4 Daval International Limited Main Business Overview
 - 13.11.5 Daval International Limited Latest Developments
- 13.12 Digna Biotech, S.L.
 - 13.12.1 Digna Biotech, S.L. Company Information
 - 13.12.2 Digna Biotech, S.L. Systemic Sclerosis Drug Product Portfolios and Specifications
 - 13.12.3 Digna Biotech, S.L. Systemic Sclerosis Drug Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.12.4 Digna Biotech, S.L. Main Business Overview
 - 13.12.5 Digna Biotech, S.L. Latest Developments
- 13.13 F. Hoffmann-La Roche Ltd.
 - 13.13.1 F. Hoffmann-La Roche Ltd. Company Information
 - 13.13.2 F. Hoffmann-La Roche Ltd. Systemic Sclerosis Drug Product Portfolios and Specifications
 - 13.13.3 F. Hoffmann-La Roche Ltd. Systemic Sclerosis Drug Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.13.4 F. Hoffmann-La Roche Ltd. Main Business Overview
 - 13.13.5 F. Hoffmann-La Roche Ltd. Latest Developments
- 13.14 Fibrocell Science, Inc.

- 13.14.1 Fibrocell Science, Inc. Company Information
- 13.14.2 Fibrocell Science, Inc. Systemic Sclerosis Drug Product Portfolios and Specifications
- 13.14.3 Fibrocell Science, Inc. Systemic Sclerosis Drug Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.14.4 Fibrocell Science, Inc. Main Business Overview
- 13.14.5 Fibrocell Science, Inc. Latest Developments
- 13.15 GenKyoTex S.A.
 - 13.15.1 GenKyoTex S.A. Company Information
 - 13.15.2 GenKyoTex S.A. Systemic Sclerosis Drug Product Portfolios and Specifications
 - 13.15.3 GenKyoTex S.A. Systemic Sclerosis Drug Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.15.4 GenKyoTex S.A. Main Business Overview
 - 13.15.5 GenKyoTex S.A. Latest Developments
- 13.16 GlaxoSmithKline Plc
 - 13.16.1 GlaxoSmithKline Plc Company Information
 - 13.16.2 GlaxoSmithKline Plc Systemic Sclerosis Drug Product Portfolios and Specifications
 - 13.16.3 GlaxoSmithKline Plc Systemic Sclerosis Drug Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.16.4 GlaxoSmithKline Plc Main Business Overview
 - 13.16.5 GlaxoSmithKline Plc Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Systemic Sclerosis Drug Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & (\$ millions)

Table 2. Systemic Sclerosis Drug Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & (\$ millions)

Table 3. Major Players of ARG-201

Table 4. Major Players of Belimumab

Table 5. Major Players of BL-1110

Table 6. Major Players of BOT-191

Table 7. Major Players of C-82

Table 8. Major Players of Others

Table 9. Global Systemic Sclerosis Drug Sales by Type (2019-2024) & (K Pcs)

Table 10. Global Systemic Sclerosis Drug Sales Market Share by Type (2019-2024)

Table 11. Global Systemic Sclerosis Drug Revenue by Type (2019-2024) & (\$ million)

Table 12. Global Systemic Sclerosis Drug Revenue Market Share by Type (2019-2024)

Table 13. Global Systemic Sclerosis Drug Sale Price by Type (2019-2024) & (USD/Pcs)

Table 14. Global Systemic Sclerosis Drug Sales by Application (2019-2024) & (K Pcs)

Table 15. Global Systemic Sclerosis Drug Sales Market Share by Application (2019-2024)

Table 16. Global Systemic Sclerosis Drug Revenue by Application (2019-2024)

Table 17. Global Systemic Sclerosis Drug Revenue Market Share by Application (2019-2024)

Table 18. Global Systemic Sclerosis Drug Sale Price by Application (2019-2024) & (USD/Pcs)

Table 19. Global Systemic Sclerosis Drug Sales by Company (2019-2024) & (K Pcs)

Table 20. Global Systemic Sclerosis Drug Sales Market Share by Company (2019-2024)

Table 21. Global Systemic Sclerosis Drug Revenue by Company (2019-2024) (\$ Millions)

Table 22. Global Systemic Sclerosis Drug Revenue Market Share by Company (2019-2024)

Table 23. Global Systemic Sclerosis Drug Sale Price by Company (2019-2024) & (USD/Pcs)

Table 24. Key Manufacturers Systemic Sclerosis Drug Producing Area Distribution and Sales Area

Table 25. Players Systemic Sclerosis Drug Products Offered

Table 26. Systemic Sclerosis Drug Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)

Table 27. New Products and Potential Entrants

Table 28. Mergers & Acquisitions, Expansion

Table 29. Global Systemic Sclerosis Drug Sales by Geographic Region (2019-2024) & (K Pcs)

Table 30. Global Systemic Sclerosis Drug Sales Market Share Geographic Region (2019-2024)

Table 31. Global Systemic Sclerosis Drug Revenue by Geographic Region (2019-2024) & (\$ millions)

Table 32. Global Systemic Sclerosis Drug Revenue Market Share by Geographic Region (2019-2024)

Table 33. Global Systemic Sclerosis Drug Sales by Country/Region (2019-2024) & (K Pcs)

Table 34. Global Systemic Sclerosis Drug Sales Market Share by Country/Region (2019-2024)

Table 35. Global Systemic Sclerosis Drug Revenue by Country/Region (2019-2024) & (\$ millions)

Table 36. Global Systemic Sclerosis Drug Revenue Market Share by Country/Region (2019-2024)

Table 37. Americas Systemic Sclerosis Drug Sales by Country (2019-2024) & (K Pcs)

Table 38. Americas Systemic Sclerosis Drug Sales Market Share by Country (2019-2024)

Table 39. Americas Systemic Sclerosis Drug Revenue by Country (2019-2024) & (\$ Millions)

Table 40. Americas Systemic Sclerosis Drug Revenue Market Share by Country (2019-2024)

Table 41. Americas Systemic Sclerosis Drug Sales by Type (2019-2024) & (K Pcs)

Table 42. Americas Systemic Sclerosis Drug Sales by Application (2019-2024) & (K Pcs)

Table 43. APAC Systemic Sclerosis Drug Sales by Region (2019-2024) & (K Pcs)

Table 44. APAC Systemic Sclerosis Drug Sales Market Share by Region (2019-2024)

Table 45. APAC Systemic Sclerosis Drug Revenue by Region (2019-2024) & (\$ Millions)

Table 46. APAC Systemic Sclerosis Drug Revenue Market Share by Region (2019-2024)

Table 47. APAC Systemic Sclerosis Drug Sales by Type (2019-2024) & (K Pcs)

Table 48. APAC Systemic Sclerosis Drug Sales by Application (2019-2024) & (K Pcs)

Table 49. Europe Systemic Sclerosis Drug Sales by Country (2019-2024) & (K Pcs)

Table 50. Europe Systemic Sclerosis Drug Sales Market Share by Country (2019-2024)

Table 51. Europe Systemic Sclerosis Drug Revenue by Country (2019-2024) & (\$ Millions)

Table 52. Europe Systemic Sclerosis Drug Revenue Market Share by Country (2019-2024)

Table 53. Europe Systemic Sclerosis Drug Sales by Type (2019-2024) & (K Pcs)

Table 54. Europe Systemic Sclerosis Drug Sales by Application (2019-2024) & (K Pcs)

Table 55. Middle East & Africa Systemic Sclerosis Drug Sales by Country (2019-2024) & (K Pcs)

Table 56. Middle East & Africa Systemic Sclerosis Drug Sales Market Share by Country (2019-2024)

Table 57. Middle East & Africa Systemic Sclerosis Drug Revenue by Country (2019-2024) & (\$ Millions)

Table 58. Middle East & Africa Systemic Sclerosis Drug Revenue Market Share by Country (2019-2024)

Table 59. Middle East & Africa Systemic Sclerosis Drug Sales by Type (2019-2024) & (K Pcs)

Table 60. Middle East & Africa Systemic Sclerosis Drug Sales by Application (2019-2024) & (K Pcs)

Table 61. Key Market Drivers & Growth Opportunities of Systemic Sclerosis Drug

Table 62. Key Market Challenges & Risks of Systemic Sclerosis Drug

Table 63. Key Industry Trends of Systemic Sclerosis Drug

Table 64. Systemic Sclerosis Drug Raw Material

Table 65. Key Suppliers of Raw Materials

Table 66. Systemic Sclerosis Drug Distributors List

Table 67. Systemic Sclerosis Drug Customer List

Table 68. Global Systemic Sclerosis Drug Sales Forecast by Region (2025-2030) & (K Pcs)

Table 69. Global Systemic Sclerosis Drug Revenue Forecast by Region (2025-2030) & (\$ millions)

Table 70. Americas Systemic Sclerosis Drug Sales Forecast by Country (2025-2030) & (K Pcs)

Table 71. Americas Systemic Sclerosis Drug Revenue Forecast by Country (2025-2030) & (\$ millions)

Table 72. APAC Systemic Sclerosis Drug Sales Forecast by Region (2025-2030) & (K Pcs)

Table 73. APAC Systemic Sclerosis Drug Revenue Forecast by Region (2025-2030) & (\$ millions)

Table 74. Europe Systemic Sclerosis Drug Sales Forecast by Country (2025-2030) & (K

Pcs)

Table 75. Europe Systemic Sclerosis Drug Revenue Forecast by Country (2025-2030) & (\$ millions)

Table 76. Middle East & Africa Systemic Sclerosis Drug Sales Forecast by Country (2025-2030) & (K Pcs)

Table 77. Middle East & Africa Systemic Sclerosis Drug Revenue Forecast by Country (2025-2030) & (\$ millions)

Table 78. Global Systemic Sclerosis Drug Sales Forecast by Type (2025-2030) & (K Pcs)

Table 79. Global Systemic Sclerosis Drug Revenue Forecast by Type (2025-2030) & (\$ Millions)

Table 80. Global Systemic Sclerosis Drug Sales Forecast by Application (2025-2030) & (K Pcs)

Table 81. Global Systemic Sclerosis Drug Revenue Forecast by Application (2025-2030) & (\$ Millions)

Table 82. Allergan Plc Basic Information, Systemic Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 83. Allergan Plc Systemic Sclerosis Drug Product Portfolios and Specifications

Table 84. Allergan Plc Systemic Sclerosis Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 85. Allergan Plc Main Business

Table 86. Allergan Plc Latest Developments

Table 87. Angion Biomedica Corp. Basic Information, Systemic Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 88. Angion Biomedica Corp. Systemic Sclerosis Drug Product Portfolios and Specifications

Table 89. Angion Biomedica Corp. Systemic Sclerosis Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 90. Angion Biomedica Corp. Main Business

Table 91. Angion Biomedica Corp. Latest Developments

Table 92. arGentis Pharmaceuticals, LLC Basic Information, Systemic Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 93. arGentis Pharmaceuticals, LLC Systemic Sclerosis Drug Product Portfolios and Specifications

Table 94. arGentis Pharmaceuticals, LLC Systemic Sclerosis Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 95. arGentis Pharmaceuticals, LLC Main Business

Table 96. arGentis Pharmaceuticals, LLC Latest Developments

Table 97. Bayer AG Basic Information, Systemic Sclerosis Drug Manufacturing Base,

Sales Area and Its Competitors

Table 98. Bayer AG Systemic Sclerosis Drug Product Portfolios and Specifications

Table 99. Bayer AG Systemic Sclerosis Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 100. Bayer AG Main Business

Table 101. Bayer AG Latest Developments

Table 102. BioLineRx, Ltd. Basic Information, Systemic Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 103. BioLineRx, Ltd. Systemic Sclerosis Drug Product Portfolios and Specifications

Table 104. BioLineRx, Ltd. Systemic Sclerosis Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 105. BioLineRx, Ltd. Main Business

Table 106. BioLineRx, Ltd. Latest Developments

Table 107. BiOrion Technologies B.V. Basic Information, Systemic Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 108. BiOrion Technologies B.V. Systemic Sclerosis Drug Product Portfolios and Specifications

Table 109. BiOrion Technologies B.V. Systemic Sclerosis Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 110. BiOrion Technologies B.V. Main Business

Table 111. BiOrion Technologies B.V. Latest Developments

Table 112. Boehringer Ingelheim GmbH Basic Information, Systemic Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 113. Boehringer Ingelheim GmbH Systemic Sclerosis Drug Product Portfolios and Specifications

Table 114. Boehringer Ingelheim GmbH Systemic Sclerosis Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 115. Boehringer Ingelheim GmbH Main Business

Table 116. Boehringer Ingelheim GmbH Latest Developments

Table 117. Bristol-Myers Squibb Company Basic Information, Systemic Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 118. Bristol-Myers Squibb Company Systemic Sclerosis Drug Product Portfolios and Specifications

Table 119. Bristol-Myers Squibb Company Systemic Sclerosis Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 120. Bristol-Myers Squibb Company Main Business

Table 121. Bristol-Myers Squibb Company Latest Developments

Table 122. Corbus pharmaceuticals, Inc. Basic Information, Systemic Sclerosis Drug

Manufacturing Base, Sales Area and Its Competitors

Table 123. Corbus pharmaceuticals, Inc. Systemic Sclerosis Drug Product Portfolios and Specifications

Table 124. Corbus pharmaceuticals, Inc. Systemic Sclerosis Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 125. Corbus pharmaceuticals, Inc. Main Business

Table 126. Corbus pharmaceuticals, Inc. Latest Developments

Table 127. CSL Limited Basic Information, Systemic Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 128. CSL Limited Systemic Sclerosis Drug Product Portfolios and Specifications

Table 129. CSL Limited Systemic Sclerosis Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 130. CSL Limited Main Business

Table 131. CSL Limited Latest Developments

Table 132. Daval International Limited Basic Information, Systemic Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 133. Daval International Limited Systemic Sclerosis Drug Product Portfolios and Specifications

Table 134. Daval International Limited Systemic Sclerosis Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 135. Daval International Limited Main Business

Table 136. Daval International Limited Latest Developments

Table 137. Digna Biotech, S.L. Basic Information, Systemic Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 138. Digna Biotech, S.L. Systemic Sclerosis Drug Product Portfolios and Specifications

Table 139. Digna Biotech, S.L. Systemic Sclerosis Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 140. Digna Biotech, S.L. Main Business

Table 141. Digna Biotech, S.L. Latest Developments

Table 142. F. Hoffmann-La Roche Ltd. Basic Information, Systemic Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 143. F. Hoffmann-La Roche Ltd. Systemic Sclerosis Drug Product Portfolios and Specifications

Table 144. F. Hoffmann-La Roche Ltd. Systemic Sclerosis Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 145. F. Hoffmann-La Roche Ltd. Main Business

Table 146. F. Hoffmann-La Roche Ltd. Latest Developments

Table 147. Fibrocell Science, Inc. Basic Information, Systemic Sclerosis Drug

Manufacturing Base, Sales Area and Its Competitors

Table 148. Fibrocell Science, Inc. Systemic Sclerosis Drug Product Portfolios and Specifications

Table 149. Fibrocell Science, Inc. Systemic Sclerosis Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 150. Fibrocell Science, Inc. Main Business

Table 151. Fibrocell Science, Inc. Latest Developments

Table 152. GenKyoTex S.A. Basic Information, Systemic Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 153. GenKyoTex S.A. Systemic Sclerosis Drug Product Portfolios and Specifications

Table 154. GenKyoTex S.A. Systemic Sclerosis Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 155. GenKyoTex S.A. Main Business

Table 156. GenKyoTex S.A. Latest Developments

Table 157. GlaxoSmithKline Plc Basic Information, Systemic Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 158. GlaxoSmithKline Plc Systemic Sclerosis Drug Product Portfolios and Specifications

Table 159. GlaxoSmithKline Plc Systemic Sclerosis Drug Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 160. GlaxoSmithKline Plc Main Business

Table 161. GlaxoSmithKline Plc Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Systemic Sclerosis Drug
- Figure 2. Systemic Sclerosis Drug Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Systemic Sclerosis Drug Sales Growth Rate 2019-2030 (K Pcs)
- Figure 7. Global Systemic Sclerosis Drug Revenue Growth Rate 2019-2030 (\$ Millions)
- Figure 8. Systemic Sclerosis Drug Sales by Region (2019, 2023 & 2030) & (\$ Millions)
- Figure 9. Product Picture of ARG-201
- Figure 10. Product Picture of Belimumab
- Figure 11. Product Picture of BL-1110
- Figure 12. Product Picture of BOT-191
- Figure 13. Product Picture of C-82
- Figure 14. Product Picture of Others
- Figure 15. Global Systemic Sclerosis Drug Sales Market Share by Type in 2023
- Figure 16. Global Systemic Sclerosis Drug Revenue Market Share by Type (2019-2024)
- Figure 17. Systemic Sclerosis Drug Consumed in Hospital
- Figure 18. Global Systemic Sclerosis Drug Market: Hospital (2019-2024) & (K Pcs)
- Figure 19. Systemic Sclerosis Drug Consumed in Clinic
- Figure 20. Global Systemic Sclerosis Drug Market: Clinic (2019-2024) & (K Pcs)
- Figure 21. Systemic Sclerosis Drug Consumed in ASCs
- Figure 22. Global Systemic Sclerosis Drug Market: ASCs (2019-2024) & (K Pcs)
- Figure 23. Systemic Sclerosis Drug Consumed in Others
- Figure 24. Global Systemic Sclerosis Drug Market: Others (2019-2024) & (K Pcs)
- Figure 25. Global Systemic Sclerosis Drug Sales Market Share by Application (2023)
- Figure 26. Global Systemic Sclerosis Drug Revenue Market Share by Application in 2023
- Figure 27. Systemic Sclerosis Drug Sales Market by Company in 2023 (K Pcs)
- Figure 28. Global Systemic Sclerosis Drug Sales Market Share by Company in 2023
- Figure 29. Systemic Sclerosis Drug Revenue Market by Company in 2023 (\$ Million)
- Figure 30. Global Systemic Sclerosis Drug Revenue Market Share by Company in 2023
- Figure 31. Global Systemic Sclerosis Drug Sales Market Share by Geographic Region (2019-2024)
- Figure 32. Global Systemic Sclerosis Drug Revenue Market Share by Geographic Region in 2023

- Figure 33. Americas Systemic Sclerosis Drug Sales 2019-2024 (K Pcs)
- Figure 34. Americas Systemic Sclerosis Drug Revenue 2019-2024 (\$ Millions)
- Figure 35. APAC Systemic Sclerosis Drug Sales 2019-2024 (K Pcs)
- Figure 36. APAC Systemic Sclerosis Drug Revenue 2019-2024 (\$ Millions)
- Figure 37. Europe Systemic Sclerosis Drug Sales 2019-2024 (K Pcs)
- Figure 38. Europe Systemic Sclerosis Drug Revenue 2019-2024 (\$ Millions)
- Figure 39. Middle East & Africa Systemic Sclerosis Drug Sales 2019-2024 (K Pcs)
- Figure 40. Middle East & Africa Systemic Sclerosis Drug Revenue 2019-2024 (\$ Millions)
- Figure 41. Americas Systemic Sclerosis Drug Sales Market Share by Country in 2023
- Figure 42. Americas Systemic Sclerosis Drug Revenue Market Share by Country in 2023
- Figure 43. Americas Systemic Sclerosis Drug Sales Market Share by Type (2019-2024)
- Figure 44. Americas Systemic Sclerosis Drug Sales Market Share by Application (2019-2024)
- Figure 45. United States Systemic Sclerosis Drug Revenue Growth 2019-2024 (\$ Millions)
- Figure 46. Canada Systemic Sclerosis Drug Revenue Growth 2019-2024 (\$ Millions)
- Figure 47. Mexico Systemic Sclerosis Drug Revenue Growth 2019-2024 (\$ Millions)
- Figure 48. Brazil Systemic Sclerosis Drug Revenue Growth 2019-2024 (\$ Millions)
- Figure 49. APAC Systemic Sclerosis Drug Sales Market Share by Region in 2023
- Figure 50. APAC Systemic Sclerosis Drug Revenue Market Share by Regions in 2023
- Figure 51. APAC Systemic Sclerosis Drug Sales Market Share by Type (2019-2024)
- Figure 52. APAC Systemic Sclerosis Drug Sales Market Share by Application (2019-2024)
- Figure 53. China Systemic Sclerosis Drug Revenue Growth 2019-2024 (\$ Millions)
- Figure 54. Japan Systemic Sclerosis Drug Revenue Growth 2019-2024 (\$ Millions)
- Figure 55. South Korea Systemic Sclerosis Drug Revenue Growth 2019-2024 (\$ Millions)
- Figure 56. Southeast Asia Systemic Sclerosis Drug Revenue Growth 2019-2024 (\$ Millions)
- Figure 57. India Systemic Sclerosis Drug Revenue Growth 2019-2024 (\$ Millions)
- Figure 58. Australia Systemic Sclerosis Drug Revenue Growth 2019-2024 (\$ Millions)
- Figure 59. China Taiwan Systemic Sclerosis Drug Revenue Growth 2019-2024 (\$ Millions)
- Figure 60. Europe Systemic Sclerosis Drug Sales Market Share by Country in 2023
- Figure 61. Europe Systemic Sclerosis Drug Revenue Market Share by Country in 2023
- Figure 62. Europe Systemic Sclerosis Drug Sales Market Share by Type (2019-2024)
- Figure 63. Europe Systemic Sclerosis Drug Sales Market Share by Application

(2019-2024)

Figure 64. Germany Systemic Sclerosis Drug Revenue Growth 2019-2024 (\$ Millions)

Figure 65. France Systemic Sclerosis Drug Revenue Growth 2019-2024 (\$ Millions)

Figure 66. UK Systemic Sclerosis Drug Revenue Growth 2019-2024 (\$ Millions)

Figure 67. Italy Systemic Sclerosis Drug Revenue Growth 2019-2024 (\$ Millions)

Figure 68. Russia Systemic Sclerosis Drug Revenue Growth 2019-2024 (\$ Millions)

Figure 69. Middle East & Africa Systemic Sclerosis Drug Sales Market Share by Country in 2023

Figure 70. Middle East & Africa Systemic Sclerosis Drug Revenue Market Share by Country in 2023

Figure 71. Middle East & Africa Systemic Sclerosis Drug Sales Market Share by Type (2019-2024)

Figure 72. Middle East & Africa Systemic Sclerosis Drug Sales Market Share by Application (2019-2024)

Figure 73. Egypt Systemic Sclerosis Drug Revenue Growth 2019-2024 (\$ Millions)

Figure 74. South Africa Systemic Sclerosis Drug Revenue Growth 2019-2024 (\$ Millions)

Figure 75. Israel Systemic Sclerosis Drug Revenue Growth 2019-2024 (\$ Millions)

Figure 76. Turkey Systemic Sclerosis Drug Revenue Growth 2019-2024 (\$ Millions)

Figure 77. GCC Country Systemic Sclerosis Drug Revenue Growth 2019-2024 (\$ Millions)

Figure 78. Manufacturing Cost Structure Analysis of Systemic Sclerosis Drug in 2023

Figure 79. Manufacturing Process Analysis of Systemic Sclerosis Drug

Figure 80. Industry Chain Structure of Systemic Sclerosis Drug

Figure 81. Channels of Distribution

Figure 82. Global Systemic Sclerosis Drug Sales Market Forecast by Region (2025-2030)

Figure 83. Global Systemic Sclerosis Drug Revenue Market Share Forecast by Region (2025-2030)

Figure 84. Global Systemic Sclerosis Drug Sales Market Share Forecast by Type (2025-2030)

Figure 85. Global Systemic Sclerosis Drug Revenue Market Share Forecast by Type (2025-2030)

Figure 86. Global Systemic Sclerosis Drug Sales Market Share Forecast by Application (2025-2030)

Figure 87. Global Systemic Sclerosis Drug Revenue Market Share Forecast by Application (2025-2030)

I would like to order

Product name: Global Systemic Sclerosis Drug Market Growth 2024-2030

Product link: <https://marketpublishers.com/r/GE1A189D9E9FEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GE1A189D9E9FEN.html>